Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071153 | 0.86 | MAPT (0.54) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL14764990 | 0.85 | TDP1 (0.53) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL8269374 | 0.85 | TDP1 (0.53) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL18338681 | 0.83 | MAPT (0.43) | MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9860919 | 0.82 | MAPT (0.53) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL28598566 | 0.81 | MAPT (0.59) | MAPTRAB9ASMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL9861151 | 0.81 | SMN1; SMN2 (0.51) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL9861057 | 0.81 | MAPT (0.51) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2563647 | 0.80 | TDP1 (0.48) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL19133388 | 0.79 | SMN1; SMN2 (0.50) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| US-7884114-B2 | N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide for treatment of allergic rhinitis | GLAXO GROUP LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-7884114-B2 | N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide for treatment of allergic rhinitis | GLAXO GROUP LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-7884114-B2 | N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide for treatment of allergic rhinitis | GLAXO GROUP LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| EP-2185542-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20090270355-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270355-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270355-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| WO-2009021965-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021965-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270355-A1 | Compounds | CMA1, HRH4, CCL11 | MAPT 1962/4885RAB9A 247/4885SMN1; SMN2 4697/4885 |
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | HRH1, HRH2, HRH4 | MAPT 3167/4885RAB9A 1052/4885SMN1; SMN2 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.